ClinicalTrials.gg
RecruitingNCT06515132SCORS-DOCUpdated Jan 7, 2025

Efficacy and Safety of Spinal Cord Stimulation in Patients With Spinal Cord Stimulation

An interventional study of SCS Stimulation and Sham Stimulation in Disorder of Consciousness and Spinal Cord Stimulation, sponsored by Huashan Hospital. Recruiting at 3 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-07.

Sponsored by Huashan Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Consciousness Disorders with a site in China — 30 open to participants now, 31 under way, 1 of them phase 3. Consciousness Disorders · China.

Planned enrollment
22nd of 40
50 · median 60
Started
2025
with 6 others
No phase
36 of 70
18 open now
Primary completion
2025-12
later than 10 of 30 live
Registered
50th of 70
by date
Lead sponsor
3 of 70
Huashan Hospital

Among the 70 studies in Consciousness Disorders with a site in China, this one is the 22nd largest by planned enrollment of the 40 interventional ones that give a count, is one of 7 that started in 2025, is one of 36 with no phase, reaches primary completion later than 10 of the 30 other live ones, and was the 50th registered.

Consciousness Disorders

291 studies on the registry are indexed under Consciousness Disorders; 109 are open to participants now.

Browse Consciousness Disorders studies →

Open to participants now

30 of the 70 studies in Consciousness Disorders with a site in China are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 74 Consciousness Disorders studies recruiting now, 31 (42%) set no upper age limit and 24 (32%) stop at 75 or younger; 12 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Consciousness Disorders with a site in China, or all of them as a file.
02

Study summary

Investigating the efficacy and safety of spinal cord stimulation for patients with disorders of consciousness.

Read the detailed description

Disorder of Consciousness (DOC) is a highly significant and concerning consequence that frequently ensues various acute brain injuries. The DOC encompasses coma, unresponsive wakefulness syndrome (UWS), also known as persistent vegetative state (PVS), and minimally conscious state (MCS). Currently, the available treatments for arousing patients with DOC are relatively limited, encompassing pharmacotherapy, hyperbaric oxygen therapy, neuromodulation, physical rehabilitation exercises, and traditional Chinese acupuncture. Among these approaches, only amantadine and transcranial direct current stimulation have demonstrated efficacy in DOC patients; however, further extensive validation is still warranted.

In recent years, spinal cord stimulation (SCS) has emerged as a cutting-edge and extensively researched modality for arousal therapy. SCS is a form of neuromodulation therapy primarily utilized for intractable pain, diabetic neuropathy, and muscle spasticity, the therapeutic efficacy of the SCS is both significant and safe. Although preliminary studies have demonstrated the potential of SCS in promoting arousal in patients with DOC, these findings are currently limited to small sample reports. Therefore, this multicenter randomized controlled trial aims to provide robust evidence on the effectiveness of SCS in promoting arousal among patients with DOC, thereby standardizing its clinical application and offering advanced evidence-based medicine for DOC management.

03

Conditions studied

  • Disorder of Consciousness
  • Spinal Cord Stimulation

Keywords

  • Disorder of Consciousness
  • Spinal Cord Stimulation
  • Randomized clinical trail
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients between the ages of 18 and 65, experiencing DOC for a duration ranging from 3 months to 1 year following brain disease.
  • Patients diagnosed with DOC as a consequence of traumatic brain injury, hypertensive intracerebral hemorrhage, or severe cerebral infarction.
  • Patients exhibiting stable cerebral anatomy and no need for further cranioplasty or hydrocephalus shunt.
  • Patients in MCS, who fulfill at least one of the following criteria: ① Demonstrating an oriented response to noxious stimuli; ② Exhibiting sustained eye tracking behavior; ③ Displaying purposeful movements; ④ Manifesting comprehension of language or emotions and actions (often observed in specific environments such as when hearing family members crying).
  • The vital signs and state of consciousness are stable: normal body temperature, the spontaneous breathing is stable (minimal sputum production and respiratory stability without oxygen supplementation for at least 2 hours); there is no significant change in the level of consciousness for at least 1 month and more.
  • Presence of short-latency responses (N20/P25) on somatosensory evoked potentials (SEP) recorded from the median nerve in the upper limbs.
  • Written obtained from legal guardians or representatives.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of severe neurological or psychiatric disorders, or other significant diseases impacting prognosis prior to the onset of DOC;
  • Patients with for surgery, such as acute infections or coagulation disorders;
  • Patients who require short-wave diathermy treatment and are unable to undergo neurostimulation;
  • Patients with hypoxic brain injury due to suffocation, cardiac arrest, or respiratory arrest;
  • Patients with brainstem hemorrhage;
  • Pregnant women;
  • Patients who voluntarily request SCS implantation but are unwilling to cooperate with the research protocol;
  • Participants in other clinical trials.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    SCS group

    SCS stimulation therapy is initiated 1 week post-surgery, which is administered continuously for a duration of 6 months.

    Procedure: SCS Stimulation

  • Sham comparator
    Sham group

    Sham stimulation therapy is initiated 1 week post-surgery, and SCS stimulation therapy is initiated 3 months post-surgery, which is stimulated continuously for a duration of 3 months.

    Procedure: Sham Stimulation

Interventions

  • ProcedureSCS Stimulation

    Participants will accept the SCS stimulus for six months

  • ProcedureSham Stimulation

    Sham stimulation will be performed in the first three months after surgery, and SCS stimulation will be started in the fourth month after surgery

06

What researchers measure

Primary outcomes

  1. Effective rate of awakening

    The CRS-R is employed, with a minimum of 5 CRS-R assessments conducted at each follow-up time point, accompanied by simultaneous video recording. And the highest value is scored as a state of consciousness. The clinical assessment of participants' consciousness is deemed significantly improved when it fulfills the following criteria: a) MCS- recover to consciousness level of MCS+ or higher; b) MCS status (MCS- or MCS+) recover to emergence from MCS (restoration of functional communication).

    Time frame: SCS stimulation for 3 months after operation

Secondary outcomes

  1. The difference of CRS-R scale relative to baseline between SCS group and Sham group

    The Coma Recovery Scale-Revised (CRS-R) is a standardized neurobehavioral assessment measure designed for use in patients with disorders of consciousness. It has good validity, reliability and practicability.

    Time frame: SCS stimulation for 14 days, 1-month-postoperative-stimulation, 3-month-postoperative-stimulation, 6-month-postoperative-stimulation

  2. The difference of SECONDs scale relative to baseline between SCS group and Sham group

    The Simplified Evaluation of CONsciousness Disorders (SECONDs) is a fast tool to assess consciousness in brain-injured patients.

    Time frame: SCS stimulation for 14 days, 1-month-postoperative-stimulation, 3-month-postoperative-stimulation, 6-month-postoperative-stimulation

  3. The difference of modified Ashworth scale relative to baseline between SCS group and Sham group

    The modified Ashworth scale is the most universally accepted clinical tool used to measure the increase of muscle tone.

    Time frame: SCS stimulation for 14 days, 1-month-postoperative-stimulation, 3-month-postoperative-stimulation, 6-month-postoperative-stimulation

  4. The NCS-R scale relative to baseline between SCS group and Sham group

    The Nociception Coma Scale-Revised (NCS-R) was developed to help assess pain in patients with disorders of consciousness (DOC). Several studies have shown its sensitivity in assessing response to acute noxious stimuli.

    Time frame: SCS stimulation for 14 days, 1-month-postoperative-stimulation, 3-month-postoperative-stimulation, 6-month-postoperative-stimulation

  5. The difference of effective rate of awakening between SCS group and Sham group by SECONDs scale

    Time frame: SCS stimulation for 3-month-postoperative-stimulation

  6. SCS stimulation for 6-month-postoperative-stimulation, the difference of effective rate of awakening between SCS group and Sham group by CRS-R scale

    Time frame: SCS stimulation for 6-month-postoperative-stimulation

  7. The difference of effective rate of awakening between SCS group and Sham group by SECONDs scale

    Time frame: SCS stimulation for 6-month-postoperative-stimulation

  8. The difference of recovery trajectories of consciousness level between SCS group and Sham group

    Time frame: SCS stimulation for 6-month-postoperative-stimulation

  9. The difference of effective rate of awakening of 3 month s of sham stimulation and 3 month s of SCS stimulation in Sham group

    Time frame: 6-month-postoperation

Other outcomes

  1. Security outcome

    Incidence of postoperative infections within 3 months after operation

    Time frame: 3 months after operation

  2. Security outcome

    Incidence of postoperative hemorrhage within 3 months after operation

    Time frame: 3 months after operation

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • van Erp WS, Lavrijsen JC, Vos PE, Bor H, Laureys S, Koopmans RT. The vegetative state: prevalence, misdiagnosis, and treatment limitations. J Am Med Dir Assoc. 2015 Jan;16(1):85.e9-85.e14. doi: 10.1016/j.jamda.2014.10.014. Erratum In: J Am Med Dir Assoc. 2019 May;20(5):652. doi: 10.1016/j.jamda.2019.01.145. PubMed 25528282 ↗
  • Maas AIR, Menon DK, Manley GT, Abrams M, Akerlund C, Andelic N, Aries M, Bashford T, Bell MJ, Bodien YG, Brett BL, Buki A, Chesnut RM, Citerio G, Clark D, Clasby B, Cooper DJ, Czeiter E, Czosnyka M, Dams-O'Connor K, De Keyser V, Diaz-Arrastia R, Ercole A, van Essen TA, Falvey E, Ferguson AR, Figaji A, Fitzgerald M, Foreman B, Gantner D, Gao G, Giacino J, Gravesteijn B, Guiza F, Gupta D, Gurnell M, Haagsma JA, Hammond FM, Hawryluk G, Hutchinson P, van der Jagt M, Jain S, Jain S, Jiang JY, Kent H, Kolias A, Kompanje EJO, Lecky F, Lingsma HF, Maegele M, Majdan M, Markowitz A, McCrea M, Meyfroidt G, Mikolic A, Mondello S, Mukherjee P, Nelson D, Nelson LD, Newcombe V, Okonkwo D, Oresic M, Peul W, Pisica D, Polinder S, Ponsford J, Puybasset L, Raj R, Robba C, Roe C, Rosand J, Schueler P, Sharp DJ, Smielewski P, Stein MB, von Steinbuchel N, Stewart W, Steyerberg EW, Stocchetti N, Temkin N, Tenovuo O, Theadom A, Thomas I, Espin AT, Turgeon AF, Unterberg A, Van Praag D, van Veen E, Verheyden J, Vyvere TV, Wang KKW, Wiegers EJA, Williams WH, Wilson L, Wisniewski SR, Younsi A, Yue JK, Yuh EL, Zeiler FA, Zeldovich M, Zemek R; InTBIR Participants and Investigators. Traumatic brain injury: progress and challenges in prevention, clinical care, and research. Lancet Neurol. 2022 Nov;21(11):1004-1060. doi: 10.1016/S1474-4422(22)00309-X. Epub 2022 Sep 29. Erratum In: Lancet Neurol. 2022 Dec;21(12):e10. doi: 10.1016/S1474-4422(22)00411-2. PubMed 36183712 ↗
  • Wu S, Wu B, Liu M, Chen Z, Wang W, Anderson CS, Sandercock P, Wang Y, Huang Y, Cui L, Pu C, Jia J, Zhang T, Liu X, Zhang S, Xie P, Fan D, Ji X, Wong KL, Wang L; China Stroke Study Collaboration. Stroke in China: advances and challenges in epidemiology, prevention, and management. Lancet Neurol. 2019 Apr;18(4):394-405. doi: 10.1016/S1474-4422(18)30500-3. PubMed 30878104 ↗
  • Multi-Society Task Force on PVS. Medical aspects of the persistent vegetative state (1). N Engl J Med. 1994 May 26;330(21):1499-508. doi: 10.1056/NEJM199405263302107. PubMed 7818633 ↗
  • Giacino JT, Ashwal S, Childs N, Cranford R, Jennett B, Katz DI, Kelly JP, Rosenberg JH, Whyte J, Zafonte RD, Zasler ND. The minimally conscious state: definition and diagnostic criteria. Neurology. 2002 Feb 12;58(3):349-53. doi: 10.1212/wnl.58.3.349. PubMed 11839831 ↗
  • Thibaut A, Bruno MA, Ledoux D, Demertzi A, Laureys S. tDCS in patients with disorders of consciousness: sham-controlled randomized double-blind study. Neurology. 2014 Apr 1;82(13):1112-8. doi: 10.1212/WNL.0000000000000260. Epub 2014 Feb 26. PubMed 24574549 ↗
  • Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, Eifert B, Long D, Katz DI, Cho S, Yablon SA, Luther M, Hammond FM, Nordenbo A, Novak P, Mercer W, Maurer-Karattup P, Sherer M. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012 Mar 1;366(9):819-26. doi: 10.1056/NEJMoa1102609. PubMed 22375973 ↗
  • Denison T, Morrell MJ. Neuromodulation in 2035: The Neurology Future Forecasting Series. Neurology. 2022 Jan 11;98(2):65-72. doi: 10.1212/WNL.0000000000013061. PubMed 35263267 ↗
  • Petersen EA, Stauss TG, Scowcroft JA, Brooks ES, White JL, Sills SM, Amirdelfan K, Guirguis MN, Xu J, Yu C, Nairizi A, Patterson DG, Tsoulfas KC, Creamer MJ, Galan V, Bundschu RH, Paul CA, Mehta ND, Choi H, Sayed D, Lad SP, DiBenedetto DJ, Sethi KA, Goree JH, Bennett MT, Harrison NJ, Israel AF, Chang P, Wu PW, Gekht G, Argoff CE, Nasr CE, Taylor RS, Subbaroyan J, Gliner BE, Caraway DL, Mekhail NA. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurol. 2021 Jun 1;78(6):687-698. doi: 10.1001/jamaneurol.2021.0538. PubMed 33818600 ↗
  • Hara S, Andresen H, Solheim O, Carlsen SM, Sundstrom T, Lonne G, Lonne VV, Taraldsen K, Tronvik EA, Oie LR, Gulati AM, Sagberg LM, Jakola AS, Solberg TK, Nygaard OP, Salvesen OO, Gulati S. Effect of Spinal Cord Burst Stimulation vs Placebo Stimulation on Disability in Patients With Chronic Radicular Pain After Lumbar Spine Surgery: A Randomized Clinical Trial. JAMA. 2022 Oct 18;328(15):1506-1514. doi: 10.1001/jama.2022.18231. PubMed 36255427 ↗
  • Mekhail N, Levy RM, Deer TR, Kapural L, Li S, Amirdelfan K, Hunter CW, Rosen SM, Costandi SJ, Falowski SM, Burgher AH, Pope JE, Gilmore CA, Qureshi FA, Staats PS, Scowcroft J, Carlson J, Kim CK, Yang MI, Stauss T, Poree L; Evoke Study Group. Long-term safety and efficacy of closed-loop spinal cord stimulation to treat chronic back and leg pain (Evoke): a double-blind, randomised, controlled trial. Lancet Neurol. 2020 Feb;19(2):123-134. doi: 10.1016/S1474-4422(19)30414-4. Epub 2019 Dec 20. PubMed 31870766 ↗
  • North RB, Kidd DH, Zahurak M, James CS, Long DM. Spinal cord stimulation for chronic, intractable pain: experience over two decades. Neurosurgery. 1993 Mar;32(3):384-94; discussion 394-5. doi: 10.1227/00006123-199303000-00008. PubMed 8455763 ↗
  • Funahashi K, Komai N, Ogura M, Kuwata T, Nakai M, Tsuji N. [Effects and indications of spinal cord stimulation on the vegetative syndrome]. No Shinkei Geka. 1989 Oct;17(10):917-23. Japanese. PubMed 2812256 ↗
  • Kanno T, Morita I, Yamaguchi S, Yokoyama T, Kamei Y, Anil SM, Karagiozov KL. Dorsal column stimulation in persistent vegetative state. Neuromodulation. 2009 Jan;12(1):33-8. doi: 10.1111/j.1525-1403.2009.00185.x. PubMed 22151220 ↗
  • Piedade GS, Assumpcao de Monaco B, Guest JD, Cordeiro JG. Review of spinal cord stimulation for disorders of consciousness. Curr Opin Neurol. 2023 Dec 1;36(6):507-515. doi: 10.1097/WCO.0000000000001222. Epub 2023 Oct 26. PubMed 37889524 ↗
  • Kinfe TM, Pintea B, Vatter H. Is Spinal Cord Stimulation Useful and Safe for the Treatment of Chronic Pain of Ischemic Origin? A Review. Clin J Pain. 2016 Jan;32(1):7-13. doi: 10.1097/AJP.0000000000000229. PubMed 25760739 ↗
  • Giacino JT, Katz DI, Schiff ND, Whyte J, Ashman EJ, Ashwal S, Barbano R, Hammond FM, Laureys S, Ling GSF, Nakase-Richardson R, Seel RT, Yablon S, Getchius TSD, Gronseth GS, Armstrong MJ. Practice guideline update recommendations summary: Disorders of consciousness: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research. Neurology. 2018 Sep 4;91(10):450-460. doi: 10.1212/WNL.0000000000005926. Epub 2018 Aug 8. Erratum In: Neurology. 2019 Jul 16;93(3):135. doi: 10.1212/WNL.0000000000007382. PubMed 30089618 ↗
  • Thibaut A, Schiff N, Giacino J, Laureys S, Gosseries O. Therapeutic interventions in patients with prolonged disorders of consciousness. Lancet Neurol. 2019 Jun;18(6):600-614. doi: 10.1016/S1474-4422(19)30031-6. Epub 2019 Apr 16. PubMed 31003899 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Dec 2025, 11 months later.

Of 90 non-industry interventional studies with no phase under Consciousness Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 64. This study's planned 11 months is below that.

Counting every sponsor, half of 95 studies reached it within 19 months; a quarter within 8 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2024
First posted
Jul 23, 2024
StartEst.
Jan 10, 2025
Primary completionEst.
Dec 30, 2025
CompletionEst.
May 30, 2026
Last update
Jan 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06515132
Lead sponsor
Huashan Hospital
Collaborators
Xiangya Hospital of Central South University, First Affiliated Hospital of Fujian Medical University
Responsible party
Xuehai Wu (Deputy Director of Shanghai Neurosurgical Emergency Center, Huashan Hospital) — Principal investigator
First posted
Jul 23, 2024
Start date
Jan 10, 2025 (estimated)
Primary completion
Dec 30, 2025 (estimated)
Completion
May 30, 2026 (estimated)
Last update
Jan 7, 2025

Study contacts

Xuehai Wu, Ph.D.
Contact
Wuxuehai2013@163.com
+8613764880571
Lijian Lang, M.M.
Contact
lang_lijian@163.com
+8613896851367
Xuehai Wu, Ph.D.
principal investigator · Department of Neurosurgery, Huashan Hospital, Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion